Ratings ContextVision AB

Equities

CONTX

SE0014731154

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-02 am EDT			5-day change	1st Jan Change
5.9 ^NOK	+0.68%		-3.28%	-23.38%

Apr. 03	ContextVision Announces New Image Quality Advancements in X-Ray	CI
Feb. 16	Transcript : ContextVision AB, Q4 2023 Earnings Call, Feb 16, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The firm trades with high earnings multiples: 25.54 times its 2024 earnings per share.
The company is highly valued given the cash flows generated by its activity.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CONTEXTVISION AB	-23.38%	40.96M		C-
VEEVA SYSTEMS INC.	+4.63%	32.15B		C
PRO MEDICUS LIMITED	+17.53%	7.41B		C-
SECTRA AB	+20.94%	3.85B		B-
EVOLENT HEALTH, INC.	-17.01%	3.13B		C-
OMNICELL, INC.	-22.16%	1.25B		B
LUNIT INC.	-31.01%	1.17B		-
SIMULATIONS PLUS, INC.	+4.40%	926M		C
B-SOFT CO.,LTD.	-34.81%	911M		-
VERADIGM INC.	-25.64%	842M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes